<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Paradigm Biopharmaceuticals Ltd — News on 6ix</title>
    <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd</link>
    <description>Latest news and press releases for Paradigm Biopharmaceuticals Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 04:28:03 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/paradigm-biopharmaceuticals-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836691878dffbe2df15efab.webp</url>
      <title>Paradigm Biopharmaceuticals Ltd</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd</link>
    </image>
    <item>
      <title>March 2026 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/march-2026-quarterly-activities-report-and-appendix-4c</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/march-2026-quarterly-activities-report-and-appendix-4c</guid>
      <pubDate>Mon, 27 Apr 2026 04:28:03 GMT</pubDate>
      <description>March 2026 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Paradigm Achieves 50% Patient Dosing in Phase 3</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-achieves-50percent-patient-dosing-in-phase-3</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-achieves-50percent-patient-dosing-in-phase-3</guid>
      <pubDate>Tue, 31 Mar 2026 01:43:07 GMT</pubDate>
      <description>Paradigm Achieves 50% Patient Dosing in Phase 3</description>
    </item>
    <item>
      <title>Appendix 4D and Half Year Report</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/appendix-4d-and-half-year-report-34</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/appendix-4d-and-half-year-report-34</guid>
      <pubDate>Fri, 27 Feb 2026 02:32:08 GMT</pubDate>
      <description>Appendix 4D and Half Year Report</description>
    </item>
    <item>
      <title>Drawdown of Tranche 3 under the Convertible Note Facility</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/drawdown-of-tranche-3-under-the-convertible-note-facility</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/drawdown-of-tranche-3-under-the-convertible-note-facility</guid>
      <pubDate>Wed, 18 Feb 2026 11:12:04 GMT</pubDate>
      <description>Drawdown of Tranche 3 under the Convertible Note Facility</description>
    </item>
    <item>
      <title>Published Canine Study Strengthens iPPS Phase 3 Rationale</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/published-canine-study-strengthens-ipps-phase-3-rationale</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/published-canine-study-strengthens-ipps-phase-3-rationale</guid>
      <pubDate>Wed, 11 Feb 2026 04:04:12 GMT</pubDate>
      <description>Published Canine Study Strengthens iPPS Phase 3 Rationale</description>
    </item>
    <item>
      <title>Oral OA Animal Therapy Progresses via AVet Deal</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/oral-oa-animal-therapy-progresses-via-avet-deal</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/oral-oa-animal-therapy-progresses-via-avet-deal</guid>
      <pubDate>Mon, 09 Feb 2026 03:28:15 GMT</pubDate>
      <description>Oral OA Animal Therapy Progresses via AVet Deal</description>
    </item>
    <item>
      <title>December 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/december-2025-quarterly-activities-report-and-appendix-4c</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/december-2025-quarterly-activities-report-and-appendix-4c</guid>
      <pubDate>Fri, 30 Jan 2026 03:32:09 GMT</pubDate>
      <description>December 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>iPPS Phase 2 Biomarker Results Published in Leading Journal</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/ipps-phase-2-biomarker-results-published-in-leading-journal</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/ipps-phase-2-biomarker-results-published-in-leading-journal</guid>
      <pubDate>Wed, 28 Jan 2026 06:31:03 GMT</pubDate>
      <description>iPPS Phase 2 Biomarker Results Published in Leading Journal</description>
    </item>
    <item>
      <title>Phase 3 Knee OA Trial Recruitment Update</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/phase-3-knee-oa-trial-recruitment-update</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/phase-3-knee-oa-trial-recruitment-update</guid>
      <pubDate>Tue, 23 Dec 2025 02:49:14 GMT</pubDate>
      <description>Phase 3 Knee OA Trial Recruitment Update</description>
    </item>
    <item>
      <title>Drawdown of Tranche 2 under the Convertible Note Facility</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/drawdown-of-tranche-2-under-the-convertible-note-facility</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/drawdown-of-tranche-2-under-the-convertible-note-facility</guid>
      <pubDate>Mon, 17 Nov 2025 06:28:03 GMT</pubDate>
      <description>Drawdown of Tranche 2 under the Convertible Note Facility</description>
    </item>
    <item>
      <title>September 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/september-2025-quarterly-activities-report-and-appendix-4c</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/september-2025-quarterly-activities-report-and-appendix-4c</guid>
      <pubDate>Thu, 30 Oct 2025 02:59:19 GMT</pubDate>
      <description>September 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Phase 3 Knee OA Trial Recruiting and Dosing in AUS &amp; US</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/phase-3-knee-oa-trial-recruiting-and-dosing-in-aus-and-us</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/phase-3-knee-oa-trial-recruiting-and-dosing-in-aus-and-us</guid>
      <pubDate>Tue, 30 Sep 2025 05:07:03 GMT</pubDate>
      <description>Phase 3 Knee OA Trial Recruiting and Dosing in AUS &amp; US</description>
    </item>
    <item>
      <title>Appendix 4E and 2025 Annual Report</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/appendix-4e-and-2025-annual-report-22</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/appendix-4e-and-2025-annual-report-22</guid>
      <pubDate>Fri, 29 Aug 2025 07:53:15 GMT</pubDate>
      <description>Appendix 4E and 2025 Annual Report</description>
    </item>
    <item>
      <title>June 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/june-2025-quarterly-activities-report-and-appendix-4c-1</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/june-2025-quarterly-activities-report-and-appendix-4c-1</guid>
      <pubDate>Tue, 29 Jul 2025 03:47:15 GMT</pubDate>
      <description>June 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>Paradigm Secures US$27M to Advance Phase 3 OA Trial</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-secures-usdollar27m-to-advance-phase-3-oa-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-secures-usdollar27m-to-advance-phase-3-oa-trial</guid>
      <pubDate>Tue, 01 Jul 2025 02:52:21 GMT</pubDate>
      <description>Paradigm Secures US$27M to Advance Phase 3 OA Trial</description>
    </item>
    <item>
      <title>Paradigm Strengthens OA Pipeline with Strategic Acquisition</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-strengthens-oa-pipeline-with-strategic-acquisition</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-strengthens-oa-pipeline-with-strategic-acquisition</guid>
      <pubDate>Thu, 26 Jun 2025 02:47:16 GMT</pubDate>
      <description>Paradigm Strengthens OA Pipeline with Strategic Acquisition</description>
    </item>
    <item>
      <title>PAR Receives US Ethics Approval for Phase 3</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/par-receives-us-ethics-approval-for-phase-3</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/par-receives-us-ethics-approval-for-phase-3</guid>
      <pubDate>Thu, 15 May 2025 02:45:12 GMT</pubDate>
      <description>PAR Receives US Ethics Approval for Phase 3</description>
    </item>
    <item>
      <title>March 2025 Quarterly Activities Report &amp; Appendix 4C</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/march-2025-quarterly-activities-report-and-appendix-4c-1</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/march-2025-quarterly-activities-report-and-appendix-4c-1</guid>
      <pubDate>Tue, 29 Apr 2025 08:12:13 GMT</pubDate>
      <description>March 2025 Quarterly Activities Report &amp; Appendix 4C</description>
    </item>
    <item>
      <title>S&amp;P DJI Announces March 2025 Quarterly Rebalance</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/sandp-dji-announces-march-2025-quarterly-rebalance-85</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/sandp-dji-announces-march-2025-quarterly-rebalance-85</guid>
      <pubDate>Fri, 07 Mar 2025 11:22:14 GMT</pubDate>
      <description>S&amp;P DJI Announces March 2025 Quarterly Rebalance</description>
    </item>
    <item>
      <title>Paradigm Secures Ethics Approval for Phase 3 Trial</title>
      <link>https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-secures-ethics-approval-for-phase-3-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/paradigm-biopharmaceuticals-ltd/news/paradigm-secures-ethics-approval-for-phase-3-trial</guid>
      <pubDate>Mon, 24 Feb 2025 02:27:27 GMT</pubDate>
      <description>Paradigm Secures Ethics Approval for Phase 3 Trial</description>
    </item>
  </channel>
</rss>